Enanta Pharmaceuticals Inc. (ENTA) will hold a conference call and webcast on Monday, September 29, 2025, at 8:30 a.m. ET to share topline results from its RSVHR study.RSVHR is a phase 2b trial evaluating its lead drug candidate Zelicapavir for the treatment of respiratory syncytial virus (RSV) in high-risk adults.Respiratory syncytial virus (RSV) causes severe lung infections, including bronchiolitis and pneumonia. High-risk populations include premature babies, young infants, and children. In the U.S. al ...